Theranostic radiopharmaceuticals, which combine diagnosis and therapy within a single administration, are transforming the management of cancer and other diseases.
The IAEA is inviting research organizations to participate in a new coordinated research project supporting the development and harmonization of production methods, radiolabeling strategies and quality control procedures for terbium radioisotopes, while strengthening technical capacity across participating institutions.
Also Read: King Faisal Hospital Ranks 12th Globally in Brand Finance 2026
Theranostics represents an important pillar of modern oncology, enabling more accurate diagnosis and targeted treatment. Increasing global demand is placing pressure on health systems to ensure that these technologies are not only effective, but also scalable, accessible and cost‑efficient.
Despite rapid scientific advances, producing a reliable and sustainable supply of radionuclides and radiopharmaceuticals at scale remains a key challenge. Even for well-established isotopes, constraints related to production capacity, infrastructure and global distribution continue to limit availability. Addressing these challenges is essential for expanding equitable access to precision oncology solutions globally.
